ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
CytomX Therapeutics Inc

CytomX Therapeutics Inc (CTMX)

2,40
0,03
(1,27%)
2,37
-0,03
(-1,25%)

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
2,37
( - )
Gebot
2,38
Fragen
2,48
Volumen
1.350.035
2,332 Tagesbereich 2,48
0,40 52-Wochen-Bereich 3,095
Marktkapitalisierung
Handelsende
2,37
Handelsbeginn
2,37
Letzte Trade
97
@
2.4015
Letzter Handelszeitpunkt
Finanzvolumen
US$ 3.191.781
VWAP
2,3642
Durchschnittliches Volumen (3 Mio.)
5.822.422
Ausgegebene Aktien
80.621.293
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
6,10
Gewinn pro Aktie (EPS)
0,4
Erlöse
138,1M
Nettogewinn
31,87M

Über CytomX Therapeutics Inc

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clini... CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Dover, Delaware, USA
Gegründet
-
CytomX Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CTMX. The last closing price for CytomX Therapeutics was US$2,37. Over the last year, CytomX Therapeutics shares have traded in a share price range of US$ 0,40 to US$ 3,095.

CytomX Therapeutics currently has 80.621.293 shares in issue. The market capitalisation of CytomX Therapeutics is US$191,07 million. CytomX Therapeutics has a price to earnings ratio (PE ratio) of 6.10.

CTMX Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.093.947368421052.282.5152.1515081402.39628754CS
4-0.26-9.885931558942.633.0952.07524486522.3885979CS
121.74276.190476190.633.0950.6158224221.94102067CS
261.33127.8846153851.043.0950.437018221.61577868CS
521.0782.30769230771.33.0950.422891611.5199375CS
1561.1188.09523809521.265.850.419068522.34164309CS
260-5.91-71.37681159428.2810.050.414981153.04477533CS

CTMX - Frequently Asked Questions (FAQ)

What is the current CytomX Therapeutics share price?
The current share price of CytomX Therapeutics is US$ 2,37
How many CytomX Therapeutics shares are in issue?
CytomX Therapeutics has 80.621.293 shares in issue
What is the market cap of CytomX Therapeutics?
The market capitalisation of CytomX Therapeutics is USD 191,07M
What is the 1 year trading range for CytomX Therapeutics share price?
CytomX Therapeutics has traded in the range of US$ 0,40 to US$ 3,095 during the past year
What is the PE ratio of CytomX Therapeutics?
The price to earnings ratio of CytomX Therapeutics is 6,1
What is the cash to sales ratio of CytomX Therapeutics?
The cash to sales ratio of CytomX Therapeutics is 1,41
What is the reporting currency for CytomX Therapeutics?
CytomX Therapeutics reports financial results in USD
What is the latest annual turnover for CytomX Therapeutics?
The latest annual turnover of CytomX Therapeutics is USD 138,1M
What is the latest annual profit for CytomX Therapeutics?
The latest annual profit of CytomX Therapeutics is USD 31,87M
What is the registered address of CytomX Therapeutics?
The registered address for CytomX Therapeutics is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904
What is the CytomX Therapeutics website address?
The website address for CytomX Therapeutics is www.cytomx.com
Which industry sector does CytomX Therapeutics operate in?
CytomX Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
WWWW International Inc
US$ 39,40
(15.685,26%)
730,5k
PROKProKidney Corporation
US$ 3,72
(513,36%)
340,28M
NDRAENDRA Life Sciences Inc
US$ 8,30
(140,12%)
90,55M
BTCSBTCS Inc
US$ 5,90
(110,71%)
134,38M
IROHIron Horse Acquisition Corporation
US$ 10,05
(68,34%)
5,58M
PHHPark Ha Biological Technology Company Ltd
US$ 2,99
(-92,71%)
8,94M
ABVEAbove Food Ingredients Inc
US$ 0,4425
(-34,85%)
4,57M
UBXUNITY Biotechnology Inc
US$ 0,20
(-33,44%)
3,85M
GIBOGIBO Holdings Ltd
US$ 0,0416
(-33,33%)
217,04M
BGLBlue Gold Limited
US$ 53,68
(-28,11%)
168,59k
PROKProKidney Corporation
US$ 3,72
(513,36%)
340,26M
GIBOGIBO Holdings Ltd
US$ 0,0416
(-33,33%)
217,04M
GVHGlobavend Holdings Ltd
US$ 0,0867
(6,25%)
216,28M
LCIDLucid Group Inc
US$ 2,295
(8,77%)
216,19M
ZVSAZyVersa Therapeutics Inc
US$ 0,775
(17,37%)
208,03M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock